Sweat gland disorder
MONDO:0006615A disease involving the sweat gland.
Also known as: disease of sweat gland, disease or disorder of sweat gland, disorder of sweat gland, sweat gland disease, sweat gland disease or disorder, disease of sweat glands, disorder of sweat glands
133 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug lutikizumab aims to ease painful skin lumps in major trial
Disease control OngoingThis phase 3 trial tests the drug lutikizumab against a placebo in about 1400 adults and teens with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants receive weekly shots for 16 weeks, then continue on differen…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Hope for painful skin condition: new pill trial targets hidradenitis suppurativa
Disease control OngoingThis study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. The trial includes about 1,328 adults and teens who have not improved with standard …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug eltrekibart aims to tame painful skin condition
Disease control OngoingThis study tests a new drug called eltrekibart in 352 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and inflammation. Participants receive either the drug or a placebo for about 62 weeks. The goal is to find a safe and ef…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of painful skin condition
Disease control OngoingThis phase 3 trial is testing the long-term safety of bimekizumab, a drug that targets inflammation, in 658 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils. Participants who completed a previous study will receive bimek…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for teens with severe skin disease: drug trial launches
Disease control OngoingThis study tests a drug called bimekizumab in teenagers (ages 9 to 17) with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The goal is to see how the drug moves through the body and if it is safe. About 40 participants will receive the dr…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New cream could ease painful skin bumps for HS patients
Disease control OngoingThis study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a chronic skin condition causing painful bumps and tunnels. About 550 participants will apply the cream or a placebo twice daily for several weeks. The main goal is to see …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can an oral Anti-Inflammatory drug tame a painful skin condition?
Disease control OngoingThis trial is investigating whether upadacitinib, an oral drug that blocks inflammation, can help people with moderate-to-severe hidradenitis suppurativa—a chronic skin disease causing painful lumps, abscesses, and scarring. Fifty adults will take upadacitinib daily for 24 weeks,…
Phase: PHASE2 • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New study tracks how a skin disease drug works in everyday life
Disease control OngoingThis study follows 435 adults with moderate to severe hidradenitis suppurativa (a painful skin condition) who are taking secukinumab. Researchers want to see how doctors adjust the dose over two years and how well the treatment controls symptoms like abscesses and pain. The goal …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Phase: PHASE2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for HS sufferers: Long-Term drug trial expands
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill could ease painful skin condition
Disease control OngoingThis phase 3 study tests an oral drug called remibrutinib in 565 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Participants receive one of two doses of remibrutinib or a placebo for 68 weeks. The main goal is to see …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill could ease painful skin condition
Disease control OngoingThis phase 3 trial tests an oral drug called remibrutinib in 588 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study compares two doses of the drug against a placebo over 68 weeks. The main goal is to see if the …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug trial aims to help teens with painful skin condition
Disease control OngoingThis study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study tracks how well secukinumab works for painful skin condition in daily life
Disease control OngoingThis study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for HS sufferers: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a drug keep hidradenitis suppurativa under control for years?
Disease control OngoingThis study looks at whether secukinumab can keep hidradenitis suppurativa (a painful skin condition) under control over the long term. It includes 703 adults who already completed a year of treatment with secukinumab. Researchers will measure how long the response lasts and monit…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New biologic shot aims to tame painful skin disease
Disease control OngoingThis early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose level…
Phase: PHASE1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for hidradenitis sufferers: experimental drug lutikizumab enters phase 2 trial
Disease control OngoingThis phase 2 trial tests an investigational drug called lutikizumab (ABT-981) in about 210 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing lumps and abscesses. The main study includes people who have already tried and failed anti-TNF…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Five new drugs aim to tame painful skin condition
Disease control OngoingThis study tests five different investigational drugs (iscalimab, LYS006, MAS825, remibrutinib, and ianalumab) in 248 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The main goal is to see if these drugs reduce abscesses a…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug shows promise for painful skin condition
Disease control OngoingThis study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Participants are randomly assigned to receive either the drug or a placebo, and researchers will check if the drug reduc…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New cream could ease painful skin bumps for HS sufferers
Symptom relief OngoingThis study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a condition causing painful bumps under the skin. About 550 adults with HS will use the cream or a placebo for several weeks to see if it reduces flare-ups and improves sym…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New study tracks how patients feel about their HS treatment
Symptom relief OngoingThis study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are with a new medication called secukinumab, and how it affects their quality of life. About 48 adults in the UAE who are just starting secukinumab will fill out questionnaires over a …
Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Exercise may ease daily struggles for hidradenitis patients
Symptom relief OngoingThis study looks at whether a simple home exercise program can improve strength, endurance, and quality of life for people with hidradenitis suppurativa (HS), a painful skin condition. Researchers will have 86 adults with HS follow a video-guided exercise routine 3-4 days a week.…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Laser study for HS scars pulled before it began
Symptom relief TerminatedThis study planned to test a fractional ablative erbium laser on scarring caused by hidradenitis suppurativa (HS) in the armpit area. It was designed for adults with mild HS activity and visible scars. However, the trial was withdrawn before enrolling any participants, so no resu…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Botox study for skin disease pulled before it started
Symptom relief TerminatedThis study aimed to see if Botulinum Toxin-A (Botox) could help people with hidradenitis suppurativa, a painful skin condition. It planned to enroll adults with active armpit lesions of similar severity on both sides. However, the study was withdrawn before any participants were …
Phase: PHASE4 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Gentian violet study for painful skin condition pulled before it began
Symptom relief TerminatedThis study planned to test whether gentian violet, a common purple antiseptic, could reduce redness, drainage, and pain in people with hidradenitis suppurativa (HS). Participants would have applied the treatment once and returned a month later to report changes. However, the stud…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 26, 2026 13:55 UTC
-
New online tool aims to help cities beat the heat
Knowledge-focused OngoingThis pilot trial tests an online decision support tool called Chart that helps local health departments assess heat-health risks and plan for extreme heat events. Thirty health departments will either use Chart or receive standard heat-health information. The study measures how w…
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New imaging tricks could end guesswork for hand and foot skin conditions
Knowledge-focused OngoingThis study looked at 81 adults with either palmoplantar psoriasis or palmoplantar eczema, two skin conditions that can look very similar on the palms and soles. Researchers used two special camera techniques—polarized dermoscopy and ultraviolet-induced fluorescence dermoscopy—to …
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
15,000 skin patients enrolled in massive Real-World treatment study
Knowledge-focused OngoingThis study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Patients rate their symptoms after starting secukinumab for hidradenitis suppurativa
Knowledge-focused OngoingThis study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affect…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC